Glimestar-M1 Forte Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 1mg and Metformin 1000mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and enhances peripheral insulin sensitivity, contributing to better blood glucose regulation. This fixed-dose combination is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic targets. The prolonged-release formulation ensures a steady plasma concentration, minimizing gastrointestinal side effects commonly associated with Metformin immediate-release formulations and improving patient compliance. Glimestar-M1 Forte Tablet PR should be administered with meals to reduce gastrointestinal discomfort. It is contraindicated in patients with renal impairment, hepatic dysfunction, metabolic acidosis, or known hypersensitivity to its components. Regular monitoring of blood glucose, renal function, and hepatic parameters is essential during therapy. Dose adjustments may be necessary based on clinical response and tolerability. Glimestar-M1 Forte Tablet PR offers a synergistic approach to glycemic control, combining insulin secretagogue and insulin sensitizer mechanisms, thereby aiding in the effective management of type 2 diabetes mellitus.